Advance Search
MI Zhihui, QU Jinglei, QU Xiujuan, TENG Zan, CHEN Ying, SONG Na. Analysis of small molecule tyrosine kinase inhibitor combined with monoclonal antibody of programmed death receptor-1 in treatment of patients with advanced malignant tumors of digestive system[J]. Journal of Clinical Medicine in Practice, 2021, 25(18): 60-65. DOI: 10.7619/jcmp.20211628
Citation: MI Zhihui, QU Jinglei, QU Xiujuan, TENG Zan, CHEN Ying, SONG Na. Analysis of small molecule tyrosine kinase inhibitor combined with monoclonal antibody of programmed death receptor-1 in treatment of patients with advanced malignant tumors of digestive system[J]. Journal of Clinical Medicine in Practice, 2021, 25(18): 60-65. DOI: 10.7619/jcmp.20211628
shu

Analysis of small molecule tyrosine kinase inhibitor combined with monoclonal antibody of programmed death receptor-1 in treatment of patients with advanced malignant tumors of digestive system

  • Department of Oncology, the First Hospital Affiliated to China Medical University, Shenyang, Liaoning, 110001

More Information
  • Received Date: April 16, 2021
  • Available Online: October 19, 2021
  • Published Date: September 27, 2021
    Graphical Abstract
    • Abstract
  •   Objective  To analyze the efficacy and safety of small molecule tyrosine kinase inhibitor (TKI) combined with monoclonal antibody of programmed death receptor-1 (PD-1) in the treatment of patients with advanced malignant tumors of digestive system.
      Methods  The efficacy and adverse reactions, tumor growth rate and correlation between adverse reactions and efficacy in the patients with advanced malignant tumors of digestive system by combined treatment of TKI and monoclonal antibody of PD-1 from March 2019 to February 2021 in the Internal Department of Oncology of the First Hospital of China Medical University were analyzed retrospectively.
      Results  Among the 30 included patients, 25 patients were available for efficiency evaluation. The objective response rate (ORR) and disease control rate (DCR) of cases with gastric and intestinal cancers were 0 and 58.33% respectively, the ORR and DCR of cases with liver cancer were 50.00% and 100.00% respectively, the ORR and DCR of cases with pancreatic cancer were 33.30% and 100.00% respectively, and the ORR and DCR of cases with esophageal cancer were 50.00% and 100.00% respectively. There were significant correlations between tumor growth rate, immune related adverse events and DCR (P < 0.05).
      Conclusion  TKI combined with monoclonal antibody of PD-1 shows a certain anti-tumor activity in the treatment of patients with advanced malignant tumors of digestive system, and the patients with liver cancer are prone to have more benefits from combined treatment. In the course of combined therapy, patients with slow tumor growth rate have better curative effect.
    • FullText(HTML)
    • References (28)
  • [1]
    SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
    [2]
    GHAHREMANLOO A, SOLTANI A, MODARESI S, et al. Recent advances in the clinical development of immune checkpoint blockade therapy[J]. Cellular Oncology, 2019, 42(5): 609-626. doi: 10.1007/s13402-019-00456-w
    [3]
    HUANG Y, STYLIANOPOULOS T, DUDA D G, et al. Benefits of vascular normalization are dose and time dependent-letter[J]. Cancer Research, 2013, 73(23): 7144-7146. doi: 10.1158/0008-5472.CAN-13-1989
    [4]
    KATO K, MASUISHI T, FUSHIKI K, et al. Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer[J]. Journal of Clinical Oncology, 2019, 37(Suppl 4): 84-84. http://www.sciencedirect.com/science/article/pii/S2059702921001393
    [5]
    FUKUOKA S, HARA H, TAKAHASHI N, et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)[J]. Journal of Clinical Oncology, 2019, 37(Suppl 15): 2522-2522. http://www.researchgate.net/publication/333406836_Regorafenib_plus_nivolumab_in_patients_with_advanced_gastric_GC_or_colorectal_cancer_CRC_An_open-label_dose-finding_and_dose-expansion_phase_1b_trial_REGONIVO_EPOC1603
    [6]
    LWIN Z, GOMEZ-ROCA C, SAADA-BOUZID E, et al. LBA41 LEAP-005: Phase Ⅱ study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours[J]. Annals of Oncology, 2020, 31(Suppl 4): S1170. http://www.sciencedirect.com/science/article/pii/S0923753420423531
    [7]
    XU J, ZHANG Y, JIA R, et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study[J]. Clin Cancer Res: an official journal of the American Association for Cancer Research, 2019, 25(2): 515-523. doi: 10.1158/1078-0432.CCR-18-2484
    [8]
    FOLKMAN J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1196. doi: 10.1056/NEJM197111182852108
    [9]
    JAIN, RAKESH K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia[J]. Cancer Cell, 2014, 26(5): 605-622. doi: 10.1016/j.ccell.2014.10.006
    [10]
    HENDRY S A, FARNSWORTH R H, SOLOMON B, et al. The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment[J]. Frontiers in immunology, 2016, 7: 621.
    [11]
    RINDERT M, MASSIMILIANO M, GABRIELE B. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer[J]. Seminars in Cancer Biology, 2018, 52(2): 107-116. http://www.onacademic.com/detail/journal_1000040435717410_1ae9.html
    [12]
    VORON T, COLUSSI O, MARCHETEAU E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors[J]. Journal of Experimental Medicine, 2015, 212(2): 139-148. doi: 10.1084/jem.20140559
    [13]
    HOFF S, GRVNEWALD S, RSE L, et al. 1198PImmunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer[J]. Annals of Oncology, 2017, 28(Suppl 5): 1131-1138.
    [14]
    WANG C, CHEVALIER D, SALUJA J, et al. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer[J]. The Oncologist, 2020, 25(8): 1188-1194. doi: 10.1634/theoncologist.2020-0161
    [15]
    GIBNEY G T, WEINER L M, ATKINS MBJLO. Predictive biomarkers for checkpoint inhibitor-based immunotherapy[J]. Lancet Oncology, 2016, 17(12): 542-551. doi: 10.1016/S1470-2045(16)30406-5
    [16]
    CHENG A L, HSU C, CHAN S L, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma[J]. Journal of Hepatology, 2020, 72(2): 307-319. doi: 10.1016/j.jhep.2019.09.025
    [17]
    SAMSTEIN R M, LEE C H, SHOUSHTARI A N, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types[J]. Nature Genetics, 2019, 51(2): 202-206. doi: 10.1038/s41588-018-0312-8
    [18]
    MASUISHI T, TANIGUCHI H, KAWAKAMI T, et al. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer[J]. ESMO Open, 2019, 4(6): 000584. http://www.sciencedirect.com/science/article/pii/S2059702920300934
    [19]
    PHILIPS G K, ATKINS M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies[J]. International Immunology, 2015, 27(1): 39-46. doi: 10.1093/intimm/dxu095
    [20]
    GUNTURI A, MCDERMOTT D F. Nivolumab for the treatment of cancer[J]. Expert Opinion on Investigational Drugs, 2015, 24(2): 253-60. doi: 10.1517/13543784.2015.991819
    [21]
    TOPALIAN S L, DRAKE C G, PARDOLL D M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity[J]. Current Opinion in Immunology, 2012, 24(2): 207-212. doi: 10.1016/j.coi.2011.12.009
    [22]
    GETTINGER S N, HORN L, GANDHI L, et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer[J]. Journal of Clinical Oncology, 2016, 33(18): 2004-2012. http://pubmedcentralcanada.ca/pmcc/articles/PMC4672027/
    [23]
    MCDERMOTT D F, DRAKE C G, SZNOL M, et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab[J]. Journal of Clinical Oncology, 2015, 33(18): 2013-2020. doi: 10.1200/JCO.2014.58.1041
    [24]
    TOPALIAN S L, SZNOL M, MCDERMOTT D F, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab[J]. Journal of Clinical Oncology, 2014, 32(10): 1020-1030. doi: 10.1200/JCO.2013.53.0105
    [25]
    GAUCI M L, LANOY E, CHAMPIAT S, et al. Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation[J]. Clinical Cancer Research, 2019, 25(3): 946-956. doi: 10.1158/1078-0432.CCR-18-0793
    [26]
    DIAZ L A, LE D T, YOSHINO T, et al. KEYNOTE-177: First-line, open-label, randomized, phase Ⅲstudy of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma[J]. 2016.
    [27]
    Chen L T, Kang Y K, Satoh T, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data[J]. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020, 23(3): 510-519. http://newmed.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM31863227
    [28]
    POSTOW M A. Managing immune checkpoint-blocking antibody side effects[J]. American Society of Clinical Oncology Educational Book, 2015, 35(1): 76-83. http://pdfs.semanticscholar.org/c4f8/f8c7782857e790fa07e0dbf63df979e78a86.pdf
    • Related Articles

  • Related Articles

    [1]YAO Yi, TIAN Jiaxing, DAI Xuanhui, WANG Xubo, WANG Yanmei, DONG Xin. Postoperative kinesiophobia level in patients with spinal fracture and its correlations with rehabilitation self-efficacy and rehabilitation compliance[J]. Journal of Clinical Medicine in Practice, 2024, 28(21): 127-131, 136. DOI: 10.7619/jcmp.20240616
    [2]XU Yanyan, CHEN Qian, NIU Yulin, DING Bei. Influencing factors of medication adherence among adult renal transplant recipients[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 90-94. DOI: 10.7619/jcmp.20242534
    [3]LIU Guixiang, AN Jinmei, HOU Jichong, SONG Nuan, ZHAO Yuexia. Effects of painting combined with drug intervention on mental states, compliance and quality of life in patients with anxiety disorder[J]. Journal of Clinical Medicine in Practice, 2023, 27(22): 81-85. DOI: 10.7619/jcmp.20230109
    [4]Effect of multidisciplinary cooperation on quality of life of presbycusis patients with hearing-aid[J]. Journal of Clinical Medicine in Practice, 2016, (22): 132-134,149. DOI: 10.7619/jcmp.201622041
    [5]ZHANG Hong, ZHANG Li, WU Lanhua. Influence of family nursing interventions on treatment compliance and quality of life in children with diabetes mellitus in childhood[J]. Journal of Clinical Medicine in Practice, 2016, (6): 114-116. DOI: 10.7619/jcmp.201606036
    [6]ZHANG Cuiping. The effect of the continuity nursing on the social function and quality of life of patients with coronary heart disease in the rehabilitation stage[J]. Journal of Clinical Medicine in Practice, 2015, (22): 4-6. DOI: 10.7619/jcmp.201522002
    [7]ZHU Caidi, DING Song. Influence of continuous nursing on quality of life and treatment compliance of hepatitis C patients[J]. Journal of Clinical Medicine in Practice, 2015, (18): 35-37. DOI: 10.7619/jcmp.201518012
    [8]GAO Yuhong. Effect of continuity nursing on the treatment compliance and quality of life for patients with diabetes after discharging from hospital[J]. Journal of Clinical Medicine in Practice, 2015, (14): 43-45. DOI: 10.7619/jcmp.201514014
    [9]PAN Xianling. Influence of evidence-based nursing on treatment compliance and life quality of senile patients with peptic ulcer[J]. Journal of Clinical Medicine in Practice, 2014, (12): 28-30. DOI: 10.7619/jcmp.201412009
    [10]LIU Ya-fei, MA Hai-ying. Evaluation of treatment adherence for patient with tuberculosis based chemotherapy[J]. Journal of Clinical Medicine in Practice, 2011, (7): 96-97,102. DOI: 10.3969/j.issn.1672-2353.2011.07.031

Catalog

    Get Citation
    PDF
    XML
    Article views (274) PDF downloads (17) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return